PBS indications for the IL-12/23 inhibitor ustekinumab (Stelara) have been expanded from September 1, 2017 to include adults with severe Crohn’s disease. It will be available for patients with active Crohn’s disease who have failed or cannot be managed by either conventional therapy or TNF inhibitors. Evidence comes mainly from the UNITI trials, which found ...
Stelara on the PBS for Crohns disease
By Mardi Chapman
30 Aug 2017